当前位置:首页 - 行情中心 - 华兰疫苗(301207) - 财务分析 - 现金流量表

华兰疫苗

(301207)

  

流通市值:117.13亿  总市值:117.20亿
流通股本:6.01亿   总股本:6.01亿

现金流量表

报告期2026-03-312025-12-312025-09-302025-06-30
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金229,899,517.141,280,963,765.23840,417,243.67545,178,790.44
  收到的税费返还36,819,624.97---
  收到其他与经营活动有关的现金1,552,846.9419,285,993.8725,073,444.1912,574,162.77
  经营活动现金流入小计268,271,989.051,300,249,759.1865,490,687.86557,752,953.21
  购买商品、接受劳务支付的现金67,955,224.63143,327,050.34125,460,323.9773,935,589.21
  支付给职工以及为职工支付的现金28,963,819.8892,219,897.2272,369,987.450,728,557.33
  支付的各项税费5,891,217.0254,128,194.2634,523,717.0814,211,098.1
  支付其他与经营活动有关的现金64,398,685.51653,442,412.48451,172,541.16313,099,535.45
  经营活动现金流出小计167,208,947.04943,117,554.3683,526,569.61451,974,780.09
  经营活动产生的现金流量净额101,063,042.01357,132,204.8181,964,118.25105,778,173.12
二、投资活动产生的现金流量:
  收回投资收到的现金1,662,082,180.547,946,200,737.196,174,057,527.945,153,077,109.94
  取得投资收益收到的现金26,607,354.46143,268,523.5188,582,502.9348,295,924.12
  处置固定资产、无形资产和其他长期资产收回的现金净额0187,00040,000-
  处置子公司及其他营业单位收到的现金净额0---
  收到的其他与投资活动有关的现金0---
  投资活动现金流入小计1,688,689,5358,089,656,260.76,262,680,030.875,201,373,034.06
  购建固定资产、无形资产和其他长期资产支付的现金2,049,054.969,703,311.754,196,790.734,450,229.59
  投资支付的现金1,767,000,0007,899,408,615.45,769,408,615.44,984,408,615.4
  取得子公司及其他营业单位支付的现金0---
  支付其他与投资活动有关的现金0---
  投资活动现金流出小计1,769,049,054.967,909,111,927.155,773,605,406.134,988,858,844.99
  投资活动产生的现金流量净额-80,359,519.96180,544,333.55489,074,624.74212,514,189.07
三、筹资活动产生的现金流量:
  筹资活动现金流入平衡项目0---
  筹资活动现金流入小计0---
  偿还债务支付的现金0300,000,000300,000,000300,000,000
  分配股利、利润或偿付利息支付的现金-507,893,359.75140,093,339.9559,093,339.95
  支付其他与筹资活动有关的现金0---
  筹资活动现金流出小计0807,893,359.75440,093,339.95359,093,339.95
  筹资活动产生的现金流量净额0-807,893,359.75-440,093,339.95-359,093,339.95
四、汇率变动对现金及现金等价物的影响-80,382.74120,022.51155,717.47170,007.42
五、现金及现金等价物净增加额20,623,139.31-270,096,798.89231,101,120.51-40,630,970.34
  加:期初现金及现金等价物余额352,938,221.02623,035,019.91623,035,019.91623,035,019.91
  期末现金及现金等价物余额373,561,360.33352,938,221.02854,136,140.42582,404,049.57
补充资料:
  净利润-182,919,690.84-20,797,156.8
  资产减值准备-58,207,765.52--12,277,453.7
  固定资产和投资性房地产折旧-140,427,649.91-70,079,889.34
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-140,427,649.91-70,079,889.34
  无形资产摊销-794,787.42-397,393.71
  长期待摊费用摊销---0
  处置固定资产、无形资产和其他长期资产的损失-204,773.66-0
  固定资产报废损失-97,142.75-4,139.15
  公允价值变动损失--12,726,022.07--10,279,395.19
  财务费用-2,596,205.96-2,585,223.01
  投资损失--76,806,684.63--39,067,003.76
  递延所得税-4,866,236.71--9,595,212.86
  其中:递延所得税资产减少-23,666,816.43--9,787,104.34
    递延所得税负债增加--18,800,579.72-191,891.48
  存货的减少--27,742,548.14--159,904,129.76
  经营性应收项目的减少-91,664,229.96-568,098,449.84
  经营性应付项目的增加--22,117,587.07--279,390,559.53
  其他--15,774,597.19-3,591,465.83
  现金的期末余额-352,938,221.02-582,404,049.57
  减:现金的期初余额-623,035,019.91-623,035,019.91
  加:现金等价物的期末余额---0
  减:现金等价物的期初余额---0
  现金及现金等价物的净增加额--270,096,798.89--40,630,970.34
公告日期2026-04-272026-03-282025-10-302025-08-28
审计意见(境内)标准无保留意见
TOP↑